Wells Fargo & Company MN purchased a new stake in shares of Kala Pharmaceuticals Inc (NASDAQ:KALA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 164,269 shares of the company’s stock, valued at approximately $3,752,000. Wells Fargo & Company MN owned 0.67% of Kala Pharmaceuticals at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the stock. Victory Capital Management Inc. bought a new stake in shares of Kala Pharmaceuticals during the 3rd quarter worth about $12,414,000. Bank of New York Mellon Corp bought a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $540,000. Commonwealth Equity Services Inc bought a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $360,000. EAM Investors LLC bought a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $1,353,000. Finally, American International Group Inc. bought a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $122,000. 62.96% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on KALA. BidaskClub upgraded Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Wells Fargo & Co reaffirmed a “buy” rating on shares of Kala Pharmaceuticals in a report on Friday, January 5th. Wedbush reaffirmed an “outperform” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a report on Friday, December 22nd. JPMorgan Chase & Co. set a $35.00 price target on Kala Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Zacks Investment Research cut Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $36.80.
Shares of Kala Pharmaceuticals Inc (NASDAQ KALA) opened at $15.60 on Tuesday. Kala Pharmaceuticals Inc has a twelve month low of $11.81 and a twelve month high of $26.75. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14.
Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.14). equities analysts anticipate that Kala Pharmaceuticals Inc will post -2.22 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Wells Fargo & Company MN Invests $3.75 Million in Kala Pharmaceuticals Inc (KALA)” was first reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://baseballnewssource.com/markets/wells-fargo-company-mn-invests-3-75-million-in-kala-pharmaceuticals-inc-kala-stock/1820320.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.